KR102160566B1 - Conjugate of minoxidil and peptide - Google Patents
Conjugate of minoxidil and peptide Download PDFInfo
- Publication number
- KR102160566B1 KR102160566B1 KR1020190005700A KR20190005700A KR102160566B1 KR 102160566 B1 KR102160566 B1 KR 102160566B1 KR 1020190005700 A KR1020190005700 A KR 1020190005700A KR 20190005700 A KR20190005700 A KR 20190005700A KR 102160566 B1 KR102160566 B1 KR 102160566B1
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- present
- compound
- minoxidil
- hair
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 68
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960003632 minoxidil Drugs 0.000 title claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 89
- 150000001413 amino acids Chemical group 0.000 claims description 42
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 229940024606 amino acid Drugs 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims description 2
- 235000016491 selenocysteine Nutrition 0.000 claims description 2
- 229940055619 selenocysteine Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 46
- 201000004384 Alopecia Diseases 0.000 abstract description 26
- 208000024963 hair loss Diseases 0.000 abstract description 26
- 230000003676 hair loss Effects 0.000 abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 230000003779 hair growth Effects 0.000 abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 8
- 230000003658 preventing hair loss Effects 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 230000010261 cell growth Effects 0.000 abstract description 4
- 230000001766 physiological effect Effects 0.000 abstract description 3
- 210000004209 hair Anatomy 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 20
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000006071 cream Substances 0.000 description 16
- -1 pack Substances 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 239000006210 lotion Substances 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 210000003780 hair follicle Anatomy 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 8
- 108060000903 Beta-catenin Proteins 0.000 description 7
- 102000015735 Beta-catenin Human genes 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229940058015 1,3-butylene glycol Drugs 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000007998 vessel formation Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 125000001151 peptidyl group Chemical group 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000003752 improving hair Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000000642 hair follicle dermal papilla cell Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000005937 nuclear translocation Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000751 protein extraction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 2
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 229940065115 grapefruit extract Drugs 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 239000008266 hair spray Substances 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OANWAFQRNQEDSY-DCAQKATOSA-N Arg-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N OANWAFQRNQEDSY-DCAQKATOSA-N 0.000 description 1
- YHQGEARSFILVHL-HJGDQZAQSA-N Arg-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)O YHQGEARSFILVHL-HJGDQZAQSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- XIKYNVKEUINBGL-IUCAKERBSA-N Glu-His-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O XIKYNVKEUINBGL-IUCAKERBSA-N 0.000 description 1
- VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- UMBDRSMLCUYIRI-DVJZZOLTSA-N Gly-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN)O UMBDRSMLCUYIRI-DVJZZOLTSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000144217 Limnanthes alba Species 0.000 description 1
- YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- APKRGYLBSCWJJP-FXQIFTODSA-N Pro-Ala-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O APKRGYLBSCWJJP-FXQIFTODSA-N 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 102000057209 Smad1 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- PGEFRHBWGOJPJT-KKUMJFAQSA-N Tyr-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O PGEFRHBWGOJPJT-KKUMJFAQSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- TVNASBPRZBQSLH-UHFFFAOYSA-N [benzotriazol-1-yloxy-(dimethoxyamino)methylidene]-dimethoxyazanium Chemical compound CO[N+](=C(ON1N=NC2=C1C=CC=C2)N(OC)OC)OC TVNASBPRZBQSLH-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 230000003662 hair growth rate Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Abstract
본 발명은 탈모 방지용 조성물에 관한 것으로서, 보다 상세하게는 미녹시딜과 펩타이드가 화학적으로 연결된 구조를 갖는 화합물 및 이를 포함하는 탈모 방지 또는 발모 촉진용 약학적 조성물 또는 화장료 조성물에 관한 것이다. 본 발명의 미녹시딜과 펩타이드가 화학적으로 연결된 구조를 갖는 화합물은 탈모 개선, 발모 촉진, 세포 성장 촉진 등과 같은 생리활성이 우수할 뿐만 아니라 물에서의 안정성이 우수하므로, 탈모 방지 및 발모 촉진용 조성물로서 유용하게 사용될 수 있다.The present invention relates to a composition for preventing hair loss, and more particularly, to a compound having a structure in which minoxidil and a peptide are chemically linked, and a pharmaceutical composition or cosmetic composition for preventing hair loss or promoting hair growth comprising the same. The compound having a chemically linked structure of minoxidil and peptide of the present invention is not only excellent in physiological activities such as hair loss improvement, hair growth promotion, cell growth promotion, etc., but also has excellent stability in water, so it is useful as a composition for preventing hair loss and promoting hair growth. Can be used.
Description
본 발명은 미녹시딜과 펩타이드의 결합체에 관한 것으로서, 보다 구체적으로는 미녹시딜과 펩타이드 각각의 특성은 그대로 유지하면서도, 각각의 활성이 서로 상승작용을 일으키는 결합체에 관한 것이다.The present invention relates to a conjugate of minoxidil and a peptide, and more specifically, to a conjugate in which each activity causes a synergistic effect with each other while maintaining the properties of each of minoxidil and peptide.
모낭은 포유동물 피부의 독특한 기관으로서, 원시 표피의 하부가 성장하여 보다 깊은 피부 층으로 신장된 기관이다. 모낭의 기부에는 소낭 또는 진피 유두 세포로서 알려진 세포의 플러그가 존재하며, 유두는 모낭의 정상적인 순환 및 모간의 성장에 필수적이다. 모간은 케라틴 필라멘트와 필라멘트 응집 단백질로 충전된 단단하게 밀착된 상피 세포로 제조된 트레드 형상의 구조이다.Hair follicles are unique organs of mammalian skin, where the lower part of the primitive epidermis grows and extends into a deeper layer of skin. At the base of the hair follicle is a plug of cells known as follicles or dermal papilla cells, which are essential for normal circulation of the hair follicle and for the growth of the hair shaft. The hair shaft is a tread-shaped structure made of tightly adhered epithelial cells filled with keratin filaments and filament aggregation proteins.
인간의 모발은 주기적으로 생장기, 퇴행기, 휴지기를 반복하며 모발이 빠지고 다시 생성되는 과정을 거치게 된다. 모발의 주기는 호르몬 조절이나 많은 성장인자 등의 조절을 통하여 결정되며, 심한 스트레스나 영양 결핍 등에 의해서 모발은 일찍 퇴행기를 거쳐 휴지기로 접어들어 심한 탈모 증상을 유발한다.Human hair periodically repeats the growth phase, degeneration phase, and resting phase, and the hair goes through the process of being removed and regenerated. The cycle of the hair is determined through hormonal control or control of many growth factors, and due to severe stress or nutritional deficiencies, the hair enters the cessation period early through the regression period, causing severe hair loss symptoms.
모발이 두피로부터 탈락하는 현상을 탈모라 하며, 탈모에 영향을 주는 요인으로는 기후, 빛 또는 열에 의한 노출 등의 환경적인 요인과 질병, 출산, 호르몬 분비 및 변화, 약물의 복용, 영양상태 등의 내적인 요인이 있다. 탈모는 효소작용 외에도 영양부족, 두피 건조, 스트레스 등에 의해서도 발생될 수 있는데, 이러한 원인으로 인한 탈모의 경우 충분한 영양공급, 두피관리 및 항산화 물질의 섭취 또는 투여로 탈모를 방지하고 발모를 촉진할 수 있다.Hair loss from the scalp is called hair loss, and factors affecting hair loss include environmental factors such as climate, exposure to light or heat, diseases, childbirth, hormone secretion and changes, taking drugs, and nutritional status. There is an inner factor. In addition to enzyme action, hair loss can also be caused by lack of nutrition, scalp dryness, stress, etc. In the case of hair loss due to these causes, it can prevent hair loss and promote hair growth by supplying sufficient nutrition, scalp management, and ingestion or administration of antioxidants. .
이런 탈모 현상을 치료하기 위해 지금까지는 의약품으로 여러 가지 물질 등이 사용되어 왔으나 가격이 너무 비싸거나 효능에 대한 개인차가 너무 심하다는 단점이 있었다. 그 외 화장품 제품에 있어서는 가격은 싸지만 효과가 적은 식물 추출물 등을 이용해 왔지만 그 효과는 미미하였다. 탈모에 사용되는 의약품의 대표적인 예로는 미녹시딜이 있다. 미녹시딜은 미국 FDA에서 허가되었으며, 고유한 칼륨 통로 개방제(Potassium channel opener)로서의 혈관 확장 기능 외에 휴지기의 모발주기에서 성장기로 유도하고, 유도된 성장기 모발주기를 계속 유지시키는 활성이 보고되었다. 하지만, 미녹시딜 사용시 탈모를 지연시킬 수는 있지만, 실제로 새로운 모낭의 재생을 유도하기 위한 용도로는 사용될 수 없었다. 또한, 미녹시딜은 물에 대한 용해성이 낮아 침전되어 사용이 어려운 점이 있었다. 이를 해결하기 위해서 특허문헌 1에는 미녹시딜 사용시 계면활성제를 첨가하는 기술이 개시되어 있다.To treat such a hair loss phenomenon, various substances have been used as medicines so far, but there is a disadvantage in that the price is too high or individual differences in efficacy are too severe. For other cosmetic products, plant extracts, etc., which are cheap but ineffective, have been used, but the effect was insignificant. A representative example of a medicine used for hair loss is minoxidil. Minoxidil was approved by the US FDA, and in addition to its vasodilating function as a unique potassium channel opener, it has been reported that it induces the growth phase in the telogen hair cycle and maintains the induced growth phase hair cycle. However, the use of minoxidil may delay hair loss, but it could not be used for inducing regeneration of new hair follicles. In addition, minoxidil has a low solubility in water and is difficult to use because it precipitates. In order to solve this problem,
한편, 모발의 성장 및 퇴화의 과정에는 매우 많은 요인들이 서로 연계되어 있으며, 예컨대 각질 세포 성장 인자의 촉진과, 혈관내피 성장인자의 활성을 촉진, WINT 경로를 촉진하고, BMP 경로에 관여하는 단백질들의 활성을 억제함으로서 모발의 생성을 촉진시키는 일련의 성장인자를 활용한 연구가 보고되어 왔다. 그러나, 성장인자류는 효능이 매우 뛰어난 반면, 자연형의 성장인자를 얻기 위하여 재접힘이라는 추가 공정과 시간이 요구되고, 또한 정제 과정에서 대장균 유래의 오염원을 제거하기 위한 복잡한 정제 과정을 필요로 하게 되며, 안정성 및 높은 분자량으로 인한 모발의 보호막을 쉽게 뛰어 넘지 못하는 점 등이 비싼 가격과 맞물려 활용도를 떨어뜨리게 되었다.On the other hand, many factors are linked to each other in the process of hair growth and degeneration, such as promoting keratinocyte growth factor, promoting the activity of vascular endothelial growth factor, promoting WINT pathway, and proteins involved in the BMP pathway. Studies using a series of growth factors that promote hair generation by inhibiting activity have been reported. However, while growth factors are very effective, they require an additional process and time such as refolding to obtain natural growth factors, and also require a complex purification process to remove contaminants derived from E. coli in the purification process. And, due to its stability and high molecular weight, it is difficult to jump over the protective film of hair easily, which is combined with the high price, thereby reducing its utility.
이에 본 발명자들은 천연 성장인자와 동일한 또는 유사한 기능 또는 작용을 할 수 있으면서도 천연 성장인자보다 안정성이 우수하고 천연 성장인자의 큰 분자량에 의한 문제점을 개선할 수 있는 펩타이드로서 서열번호 3의 아미노산 서열로 구성되는 노킨 펩타이드(특허문헌 2), 서열번호 2의 아미노산 서열로 구성되는 케라민2 펩타이드(특허문헌 3) 및 서열번호 1의 아미노산 서열로 구성되는 WINT 펩타이드(특허문헌 4)를 개발한 바 있다.Accordingly, the inventors of the present invention are composed of the amino acid sequence of SEQ ID NO: 3 as a peptide that can perform the same or similar function or action as a natural growth factor, but has better stability than a natural growth factor and can improve problems caused by the large molecular weight of the natural growth factor. Nokin peptide (Patent Document 2), keramine 2 peptide composed of the amino acid sequence of SEQ ID NO: 2 (Patent Document 3), and WINT peptide (Patent Document 4) composed of the amino acid sequence of SEQ ID NO: 1 have been developed.
그러나, 종래 사용되는 미녹시딜이나 상기 서열번호 1 내지 서열번호 3의 아미노산 서열로 구성되는 펩타이드들은 탈모방지 및 발모촉진 성능의 향상, 부작용의 감소, 및 물에 대한 용해도 증가라는 측면에서 여전히 개선의 필요성이 있었다.However, conventionally used minoxidil or peptides consisting of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 3 still need improvement in terms of preventing hair loss and improving hair growth promoting performance, reducing side effects, and increasing solubility in water. there was.
본 발명자들은 이와 같은 문제점을 개선하기 위하여, 미녹시딜에 상기 서열번호 1 내지 서열번호 3의 아미노산 서열로 구성되는 펩타이드를 각각 화학적으로 결합하여 미녹시딜-노킨, 미녹시딜-케라민2, 미녹시딜-WINT 펩타이드를 제작하였고, 상기 화합물들이 모발의 성장에 연계되어 있는 혈관내피 성장인자의 활성을 촉진하고, WINT 경로를 촉진하며, 모발 손실에 주요한 BMP 경로에 관여하는 단백질들의 활성을 억제하는 것을 확인함으로써 본 발명을 완성하였다.In order to improve this problem, the present inventors produced minoxidyl-nokin, minoxidyl-
본 발명은 상기와 같은 종래 발모제가 갖고 있는 문제점들을 개선하기 위한 것으로서, 천연 성장인자나 상기 서열번호 1 내지 서열번호 3의 아미노산 서열로 구성되는 펩타이드, 또는 미녹시딜과 같은 종래 발모제와 비교하여 동일하거나 더 뛰어난 탈모방지 및/또는 발모촉진 기능을 할 수 있으면서도 이들보다 물에 대한 안정성 등의 생리학적 특성이 우수한 물질을 제공하는 것을 기술적 과제로 한다.The present invention is to improve the problems of the conventional hair growth agent as described above, as compared to a natural growth factor or a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 3, or the same or more than a conventional hair growth agent such as minoxidil. It is a technical task to provide a material that can perform excellent hair loss prevention and/or hair growth promotion functions, but has superior physiological properties such as water stability than these.
상기 과제를 달성하기 위하여, 본 발명은 미녹시딜과 펩타이드가 화학적으로 결합된 구조를 갖는 화합물을 제공한다.In order to achieve the above object, the present invention provides a compound having a structure in which minoxidil and a peptide are chemically bonded.
본 발명의 한 구현예에 따르면, 상기 펩타이드는 2 내지 30개, 바람직하게는 5 내지 20개, 더욱 바람직하게는 8 내지 15개, 더욱 바람직하게는 10 내지 12개의 아미노산 서열로 이루어질 수 있지만 이에 한정되는 것은 아니다.According to one embodiment of the present invention, the peptide may consist of 2 to 30, preferably 5 to 20, more preferably 8 to 15, more preferably 10 to 12 amino acid sequences, but limited thereto. It does not become.
본 발명의 다른 구현예에 따르면, 상기 펩타이드는 수용성 펩타이드인 것이 바람직하지만 이에 한정되는 것은 아니다. 본 발명의 바람직한 구현예에 따르면, 상기 수용성 펩타이드는 친수성 측쇄를 갖는 아미노산의 비율이 50% 이상, 바람직하게는 60% 이상, 보다 바람직하게는 70% 이상, 보다 바람직하게는 80% 이상, 보다 바람직하게는 90% 이상, 가장 바람직하게는 100%로 높은 것이 바람직하다. 본 발명의 다른 바람직한 구현예에 따르면, 상기 수용성 펩타이드는 소수성 측쇄를 갖는 아미노산이 5개 이하, 바람직하게는 4개 이하, 보다 바람직하게는 3개 이하, 보다 바람직하게는 2개 이하, 보다 바람직하게는 1개 이하로 존재하며, 존재하지 않는 것이 가장 바람직하다.According to another embodiment of the present invention, the peptide is preferably a water-soluble peptide, but is not limited thereto. According to a preferred embodiment of the present invention, the water-soluble peptide has a proportion of amino acids having a hydrophilic side chain of 50% or more, preferably 60% or more, more preferably 70% or more, more preferably 80% or more, more preferably It is preferably as high as 90% or more, most preferably 100%. According to another preferred embodiment of the present invention, the water-soluble peptide has 5 or less, preferably 4 or less, more preferably 3 or less, more preferably 2 or less, more preferably 5 or less amino acids having a hydrophobic side chain. Is present as 1 or less, and most preferably not present.
본 발명의 다른 구현예에 따르면, 상기 펩타이드는 서열번호 1의 아미노산 서열로 구성되는 노킨 펩타이드, 서열번호 2의 아미노산 서열로 구성되는 케라민2 펩타이드, 또는 서열번호 3의 아미노산 서열로 구성되는 WINT 펩타이드일 수 있으나 이에 한정되는 것은 아니다.According to another embodiment of the present invention, the peptide is a Nokin peptide consisting of the amino acid sequence of SEQ ID NO: 1, a
또한, 본 발명은 상기에서 개시된 어느 한 화합물을 함유하는 탈모 방지 또는 발모 촉진용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth containing any one of the compounds disclosed above.
또한, 본 발명은 상기에서 개시된 어느 한 화합물을 함유하는 탈모 방지 또는 발모 촉진용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for preventing hair loss or promoting hair growth, containing any one of the compounds disclosed above.
본 발명의 한 구현예에 따르면, 상기 화장료 조성물은 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이, 파우더, 헤어토닉, 헤어크림, 헤어로션, 헤어샴푸, 헤어린스, 헤어컨디셔너, 헤어스프레이, 헤어에어졸, 포마드, 솔젤, 에멀젼, 오일, 왁스, 에어졸과 같은 제형을 가질 수 있으나 이에 한정되는 것은 아니다.According to one embodiment of the present invention, the cosmetic composition is a flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, hair tonic, hair cream , Hair lotion, hair shampoo, hair conditioner, hair conditioner, hair spray, hair aerosol, pomade, sol gel, emulsion, oil, wax, and aerosol formulations, but are not limited thereto.
본 발명의 미녹시딜과 펩타이드가 화학적으로 결합된 구조를 갖는 화합물은 탈모 개선, 발모 촉진, 세포 성장 촉진 등과 같은 생리활성이 우수할 뿐만 아니라 물에서의 안정성 및 피부 투과율이 우수하므로, 탈모 방지 및 발모 촉진용 조성물로서 유용하게 사용될 수 있다.The compound having a structure in which minoxidil and peptide of the present invention are chemically bonded is excellent in physiological activities such as hair loss improvement, hair growth promotion, cell growth promotion, etc., as well as excellent stability in water and skin permeability, so that hair loss prevention and promotion of hair growth It can be usefully used as a solvent composition.
다만, 본 발명의 효과는 상기에서 언급한 효과로 제한되지 아니하며, 언급되지 않은 또 다른 효과들은 하기의 기재로부터 당업자에게 명확히 이해될 수 있을 것이다.However, the effects of the present invention are not limited to the above-mentioned effects, and other effects that are not mentioned will be clearly understood by those skilled in the art from the following description.
도 1은 본 발명의 화합물 및 미녹시딜의 물에 대한 용해도를 보여주는 사진이다.
도 2는 본 발명의 화합물 처리시 인간 제대정맥 혈관내피세포(Human umbilical vein endothelial cell, HUVEC)에 대한 세포 증식 정도를 나타낸 그래프이다.
도 3은 본 발명의 화합물 처리시 인간 모발 진피 유두 세포(Human Hair Dermal Papilla Cells, HHDPC)에 대한 세포 증식 정도를 나타낸 그래프이다.
도 4 내지 도 6은 본 발명의 화합물 처리시 VEGF, TGFβ1의 mRNA량을 확인한 결과이다.
도 7은 본 발명의 화합물 처리시 VEGF 단백질량을 확인한 결과이다.
도 8 및 도9는 본 발명의 화합물 처리시 혈관 형성 정도를 나타내는 이미지이다.
도 10 및 도 11은 본 발명의 화합물이 WINT의 신호 경로인 베타-카테닌의 핵 전좌에 미치는 영향을 확인한 결과이다.
도 12 및 도 13은 본 발명의 화합물이 모발 손실의 주요 인자인 BMP 신호 경로를 저해하는지 여부를 phospho-Smad1/5/8 활성화(세포질에서 핵 내로의 이동) 저해로 확인한 결과이다.
도 14 및 도 15는 본 발명의 화합물 처리시 모발 생장 정도를 확인한 결과이다.1 is a photograph showing the solubility of a compound of the present invention and minoxidil in water.
2 is a graph showing the degree of cell proliferation for human umbilical vein endothelial cells (HUVEC) when the compound of the present invention is treated.
Figure 3 is a graph showing the degree of cell proliferation for human hair dermal papilla cells (HHDPC) when the compound of the present invention is treated.
4 to 6 are results of confirming the amount of mRNA of VEGF and TGFβ1 upon treatment with the compound of the present invention.
7 is a result of confirming the amount of VEGF protein during treatment with the compound of the present invention.
8 and 9 are images showing the degree of blood vessel formation when the compound of the present invention is treated.
10 and 11 are results confirming the effect of the compound of the present invention on the nuclear translocation of beta-catenin, a signaling pathway of WINT.
12 and 13 are the results of confirming whether the compound of the present invention inhibits the BMP signaling pathway, which is a major factor in hair loss, by inhibiting phospho-Smad1/5/8 activation (migration from the cytoplasm to the nucleus).
14 and 15 are the results of confirming the degree of hair growth when the compound of the present invention is treated.
상기 과제를 달성하기 위하여, 본 발명은 미녹시딜과 펩타이드가 화학적으로 결합된 구조를 갖는 화합물을 제공한다.In order to achieve the above object, the present invention provides a compound having a structure in which minoxidil and a peptide are chemically bonded.
상기 미녹시딜은 6-아미노-1,2-디히드로-1-히드록시-2-이미노-4-페녹시피리미딘(6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidine)를 나타내는 것으로서, 하기 화학식 1로 표시되는 구조를 갖는다. The minoxidyl is 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidine (6-Amino-1,2-dihydro-1-hydroxy-2-imino-4 -phenoxypyrimidine), and has a structure represented by the following formula (1).
[화학식 1][Formula 1]
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 명세서에 있어서, "펩타이드"란 용어는 펩타이드 결합에 의해 아미노산 잔기들이 서로 결합되어 형성된 선형의 분자를 의미한다. 상기 펩타이드는 본 기술분야에 공지된 통상의 생물학적 또는 화학적 합성 방법, 특히 고상 합성 기술(solid-phase synthesis techniques)에 따라 제조될 수 있다(Merrifield, J. Amer. Chem . Soc ., 85:2149-54(1963); Stewart, et al., Solid Phase Peptide Synthesis, 2nd. ed., Pierce Chem. Co.: Rockford, 111(1984)).In the present specification, the term "peptide" refers to a linear molecule formed by bonding of amino acid residues to each other by peptide bonds. The peptides can be prepared according to conventional biological or chemical synthesis methods known in the art, in particular solid-phase synthesis techniques (Merrifield, J. Amer. Chem . Soc . , 85 :2149- 54 (1963); Stewart, et al., Solid Phase Peptide Synthesis, 2nd.ed., Pierce Chem. Co.: Rockford, 111 (1984)).
상기 펩타이드는 미녹시딜의 수용성을 증가시키기 위한 것이며, 이러한 측면에서 상기 펩타이드는 수용성 펩타이드인 것이 바람직하지만 이에 한정되는 것은 아니다. 본 발명의 한 구현예에 따르면, 상기 펩타이드는 2 내지 30개, 바람직하게는 5 내지 20개, 더욱 바람직하게는 8 내지 15개, 더욱 바람직하게는 10 내지 12개의 아미노산 서열로 이루어진다. 본 발명의 바람직한 구현예에 따르면, 상기 펩타이드는 친수성 측쇄를 갖는 아미노산의 비율이 50% 이상, 바람직하게는 60% 이상, 보다 바람직하게는 70% 이상, 보다 바람직하게는 80% 이상, 보다 바람직하게는 90% 이상, 가장 바람직하게는 100%로 높은 것이 바람직하다. 다른 한편으로, 상기 펩타이드는 소수성 측쇄를 갖는 아미노산의 비율이 50% 미만, 바람직하게는 40% 이하, 보다 바람직하게는 30% 이하, 보다 바람직하게는 20% 이하, 보다 바람직하게는 10% 이하, 가장 바람직하게는 0%로 낮은 것이 바람직하다. 본 발명에 있어서, "친수성 측쇄를 갖는 아미노산"은 아르기닌(Arg), 히스티딘(His), 리신(Lys), 아스파라긴산(Asp), 글루탐산(Glu), 세린(Ser), 트레오닌(Thr), 아스파라긴(Asn), 글루타민(Gln), 시스테인(Cys), 셀레노시스테인(Sec), 글리신(Gly) 및 프롤린(Pro)을 나타내고, "소수성 측쇄를 갖는 아미노산"은 알라닌(Ala), 발린(Val), 이소루이신(Ile), 루이신(Leu), 메티오닌(Met), 페닐알라닌(Phe), 티로신(Tyr) 및 트립토판(Trp)을 나타내지만 이에 한정되는 것은 아니며, 상기와 같은 자연계에 존재하는 아미노산들 이외에도 이들의 변형체 등도 제한없이 사용될 수 있다. 본 발명의 바람직한 구현예에 따르면, 상기 소수성 측쇄를 갖는 아미노산은 상기 펩타이드 내에 5개 이하, 바람직하게는 4개 이하, 보다 바람직하게는 3개 이하, 보다 바람직하게는 2개 이하, 보다 바람직하게는 1개 이하로 존재하며, 존재하지 않는 것이 가장 바람직하다. 본 발명의 한 구현예에 따르면, 상기 펩타이드는 서열번호 1의 아미노산 서열로 구성되는 노킨 펩타이드, 서열번호 2의 아미노산 서열로 구성되는 케라민2 펩타이드 및 서열번호 3의 아미노산 서열로 구성되는 WINT 펩타이드인 것이 바람직하지만 이에 한정되는 것은 아니다.The peptide is for increasing the water solubility of minoxidil, and in this respect, the peptide is preferably a water-soluble peptide, but is not limited thereto. According to one embodiment of the present invention, the peptide consists of a sequence of 2 to 30, preferably 5 to 20, more preferably 8 to 15, and more preferably 10 to 12 amino acids. According to a preferred embodiment of the present invention, the peptide has a proportion of amino acids having a hydrophilic side chain of 50% or more, preferably 60% or more, more preferably 70% or more, more preferably 80% or more, more preferably Is preferably 90% or more, most preferably 100%. On the other hand, the peptide has a proportion of amino acids having a hydrophobic side chain less than 50%, preferably less than 40%, more preferably less than 30%, more preferably less than 20%, more preferably less than 10%, Most preferably, it is preferably as low as 0%. In the present invention, "amino acid having a hydrophilic side chain" refers to arginine (Arg), histidine (His), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu), serine (Ser), threonine (Thr), asparagine ( Asn), glutamine (Gln), cysteine (Cys), selenocysteine (Sec), glycine (Gly) and proline (Pro), and "amino acid having a hydrophobic side chain" is alanine (Ala), valine (Val), It represents isoleucine (Ile), leucine (Leu), methionine (Met), phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp), but is not limited thereto, and amino acids present in nature as described above In addition, variations of these may also be used without limitation. According to a preferred embodiment of the present invention, the amino acid having a hydrophobic side chain is 5 or less, preferably 4 or less, more preferably 3 or less, more preferably 2 or less, more preferably in the peptide. There are no more than one, and most preferably none. According to one embodiment of the present invention, the peptide is a Nokin peptide consisting of the amino acid sequence of SEQ ID NO: 1, a
본 발명의 한 구현예에 따르면, 본 발명의 화합물은 인간 제대정맥 혈관내피세포(Human umbilical vein endothelial cell, HUVEC) 및 인간 모발 진피 유두 세포(Human Hair Dermal Papilla Cells, HHDPC)에 대한 세포의 성장 촉진능을 갖는다. 본 발명의 다른 구현예에 따르면, 본 발명의 화합물은 WNT 신호전달 경로를 활성화시켜는 기능을 가진다. 본 발명의 다른 구현예에 따르면, 본 발명의 화합물은 베타-카테닌을 핵 내로 전달한다. 본 발명의 다른 구현예에 따르면, 본 발명의 화합물은 모발 손실의 주요 인자인 BMP 신호 경로를 차단한다.According to one embodiment of the present invention, the compound of the present invention promotes the growth of cells for human umbilical vein endothelial cells (HUVEC) and human hair dermal papilla cells (HHDPC). Has the ability. According to another embodiment of the present invention, the compound of the present invention has a function of activating the WNT signaling pathway. According to another embodiment of the present invention, the compounds of the present invention deliver beta-catenin into the nucleus. According to another embodiment of the present invention, the compounds of the present invention block the BMP signaling pathway, which is a major factor in hair loss.
본 발명의 화합물은 그 자체로도 안정성이 우수하지만, 화합물에 결합된 펩타이드를 구성하는 임의의 아미노산을 변형시킴으로써 안정성이 더욱 향상될 수 있다. 본 발명의 한 구현예에 따르면, 상기 펩타이드의 N-말단은 아세틸기, 플루오레닐 메톡시 카르보닐기, 포르밀기, 팔미토일기, 미리스틸기, 스테아릴기 및 폴리에틸렌글리콜(PEG)로 이루어진 군으로부터 선택되는 보호기가 결합되어 안정성을 더욱 향상시킬 수 있다. 본 발명의 다른 구현예에 따르면, 상기 펩타이드는 아세틸기, 플루오레닐 메톡시 카르보닐기, 포르밀기, 팔미토일기, 미리스틸기, 스테아릴기 및 폴리에틸렌글리콜(PEG)로 이루어진 군으로부터 선택되는 보호기가 결합되어 안정성을 더욱 향상시킬 수 있다.The compounds of the present invention have excellent stability by themselves, but the stability can be further improved by modifying any amino acid constituting the peptide bound to the compound. According to one embodiment of the present invention, the N-terminus of the peptide is from the group consisting of acetyl group, fluorenyl methoxycarbonyl group, formyl group, palmitoyl group, myristyl group, stearyl group and polyethylene glycol (PEG). The protecting groups of choice can be combined to further improve stability. According to another embodiment of the present invention, the peptide is a protecting group selected from the group consisting of acetyl group, fluorenyl methoxycarbonyl group, formyl group, palmitoyl group, myristyl group, stearyl group and polyethylene glycol (PEG). Can be combined to further improve stability.
전술한 것과 같은 아미노산의 변형은 본 발명의 화합물의 안정성을 크게 개선하는 작용을 한다. 본 명세서에 있어서, "안정성"이란 용어는 "생체내(in vivo)" 안정성 뿐만 아니라 저장 안정성(예컨대, 상온 저장 안정성)과 같은 "시험관내(in vitro)" 안정성도 포괄하는 의미로 사용된다. 또한, 전술한 보호기는 생체내 및 시험관내에서 단백질 절단효소의 공격으로부터 본 발명의 화합물을 보호하는 작용을 한다.Modification of amino acids as described above acts to greatly improve the stability of the compounds of the present invention. In the present specification, the term "stability" is used in a sense encompassing "in vitro" stability such as storage stability (eg, room temperature storage stability) as well as "in vivo" stability. In addition, the above-described protecting group functions to protect the compounds of the present invention from attack by protein cleavage enzymes in vivo and in vitro.
또한, 본 발명은 상기 화합물을 유효성분으로 포함하는 탈모 치료 또는 개선용 조성물을 제공한다. 본 발명의 다른 구현예에 따르면, 본 발명은 상기 펩타이드를 유효성분으로 포함하는 피부 상태 개선용 조성물을 제공한다. 본 발명에 있어서, 상기 조성물은 약학적 조성물 또는 건강식품의 형태일 수 있으나 이에 한정되는 것은 아니다.In addition, the present invention provides a composition for treating or improving hair loss comprising the compound as an active ingredient. According to another embodiment of the present invention, the present invention provides a composition for improving skin conditions comprising the peptide as an active ingredient. In the present invention, the composition may be in the form of a pharmaceutical composition or health food, but is not limited thereto.
본 발명의 조성물은 전술한 본 발명의 화합물을 유효성분으로 포함하기 때문에, 이 둘 사이에 공통된 내용은 본 명세서의 과도한 복잡성을 피하기 위하여 그 기재를 생략한다.Since the composition of the present invention contains the compound of the present invention described above as an active ingredient, descriptions in common between the two are omitted in order to avoid excessive complexity of the present specification.
본 발명의 한 구현예에 따르면, 본 발명의 화합물에 의한 탈모 치료 또는 개선은 발모 촉진 또는 모발 생성이다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 화합물은 HUVEC 및 HHDPC 세포 성장 촉진 능력을 가지며, WINT 단백질의 대표적인 신호전달 경로인 베타-카테닌 신호전달 경로를 촉진시킨다. 본 발명의 다른 구현예에 따르면, 본 발명의 화합물은 모발 손실의 주요 인자인 BMP 신호 경로를 차단한다. 이러한 결과를 토대로 실시한 동물실험을 통해 본 발명의 화합물이 모발 성장을 현저하게 촉진한다는 것을 알 수 있었다. 따라서, 본 발명의 조성물은 모발의 성장 및 피부 상태의 개선에 매우 효과적이다.According to one embodiment of the present invention, the treatment or improvement of hair loss by the compounds of the present invention is promoting hair growth or generating hair. According to a preferred embodiment of the present invention, the compound of the present invention has the ability to promote HUVEC and HHDPC cell growth, and promotes the beta-catenin signaling pathway, which is a representative signaling pathway of the WINT protein. According to another embodiment of the present invention, the compounds of the present invention block the BMP signaling pathway, which is a major factor in hair loss. Animal experiments conducted on the basis of these results revealed that the compounds of the present invention remarkably promote hair growth. Therefore, the composition of the present invention is very effective in improving hair growth and skin condition.
또한, 본 발명의 한 구현예에 따르면, 본 발명의 화합물에 의한 피부 상태의 개선은 주름개선, 피부탄력 개선, 피부노화 방지, 피부보습 개선, 상처제거 또는 피부재생이다.Further, according to one embodiment of the present invention, the improvement of the skin condition by the compound of the present invention is wrinkle improvement, skin elasticity improvement, skin aging prevention, skin moisturization improvement, wound removal or skin regeneration.
본 발명의 조성물은 전술한 본 발명의 화합물을 유효성분으로 포함하기 때문에, 이 둘 사이에 공통된 내용은 본 명세서의 과도한 복잡성을 피하기 위하여 그 기재를 생략한다.Since the composition of the present invention contains the compound of the present invention described above as an active ingredient, descriptions in common between the two are omitted in order to avoid excessive complexity of the present specification.
본 발명의 바람직한 구현예에 따르면, 본 발명의 조성물은 (a) 전술한 본 발명의 화합물의 약학적 유효량; 및 (b) 약학적으로 허용되는 담체를 포함하는 약학적 조성물이다.According to a preferred embodiment of the present invention, the composition of the present invention comprises (a) a pharmaceutically effective amount of the compound of the present invention described above; And (b) is a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
본 명세서에 있어서, "약학적 유효량"이란 용어는 전술한 본 발명의 화합물의 효능 또는 활성을 달성하는 데 충분한 양을 의미한다.As used herein, the term "pharmaceutically effective amount" means an amount sufficient to achieve the above-described efficacy or activity of the compound of the present invention.
본 발명의 약학적 조성물에 포함되는 약학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하지만 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used at the time of formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, etc. It is not. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약학적 조성물은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기내에 내입시켜 제조될 수 있다. 이때, 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제, 캅셀제 또는 젤(예컨대, 하이드로젤) 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in a unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary knowledge in the art. Or it can be prepared by placing it in a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule or gel (e.g., hydrogel), and may additionally include a dispersant or a stabilizer. have.
본 발명에 따른 약학적 조성물은 임상 투여시에 경구 또는 비경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다. 즉, 본 발명의 약학적 조성물은 실제 임상 투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 생약 추출물 또는 생약 발효물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로골, 트윈 61, 카카오지, 라우린지, 글리세롤, 젤라틴 등이 사용될 수 있다.The pharmaceutical composition according to the present invention can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical formulation. That is, the pharmaceutical composition of the present invention can be administered in various oral and parenteral dosage forms at the time of actual clinical administration, but when formulated, diluents such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. Or it is formulated using excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient, such as starch, calcium carbonate, sucrose or lactose, in a herbal extract or fermented herbal product. , Gelatin, etc. are mixed to prepare it. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, syrups, etc.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. have. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as the non-aqueous solvent and the suspension. As a base for suppositories, Witepsol, Macrogol, Tween 61, cacao butter, laurin, glycerol, gelatin, and the like can be used.
투약 단위는, 예를 들면 개별 투약량의 1, 2, 3 또는 4배로, 또는 1/2, 1/3 또는 1/4배로 함유할 수 있다. 개별 투약량은 유효 약물이 1회에 투여되는 양을 함유하며, 이는 통상 1일 투여량의 전부, 1/2, 1/3 또는 1/4배에 해당한다.Dosage units may contain, for example, 1, 2, 3 or 4 times, or 1/2, 1/3 or 1/4 times the individual dosage. Individual dosages contain the amount of the effective drug administered at one time, which is usually equivalent to all, 1/2, 1/3 or 1/4 times the daily dosage.
본 발명의 약학적 조성물은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기내에 내입시켜 제조될 수 있다. 이때, 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제, 캅셀제 또는 젤(예컨대, 하이드로젤) 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in a unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary knowledge in the art. Or it can be prepared by placing it in a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule or gel (e.g., hydrogel), and may additionally include a dispersant or a stabilizer. have.
본 발명의 바람직한 구현예에 따르면, 본 발명의 조성물은 (a) 전술한 본 발명의 화합물의 화장품학적 유효량(cosmetically effective amount); 및 (b) 화장품학적으로 허용되는 담체를 포함하는 화장품 조성물이다.According to a preferred embodiment of the present invention, the composition of the present invention comprises (a) a cosmetically effective amount of the compound of the present invention described above; And (b) a cosmetically acceptable carrier.
본 명세서에 있어서, "화장품학적 유효량"이란 용어는 전술한 본 발명의 조성물의 피부 개선 효능을 달성하는 데 충분한 양을 의미한다.As used herein, the term "cosmetically effective amount" means an amount sufficient to achieve the effect of improving the skin of the composition of the present invention described above.
본 발명의 화장품 조성물은 본 기술분야에서 통상적으로 제조되는 임의의 제형으로도 제조될 수 있으며, 예를 들면, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나 이에 한정되는 것은 아니다. 보다 구체적으로는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이, 파우더, 헤어토닉, 헤어크림, 헤어로션, 헤어샴푸, 헤어린스, 헤어컨디셔너, 헤어스프레이, 헤어에어졸, 포마드, 젤 등과 같이 용액, 솔젤, 에멀젼, 오일, 왁스, 에어졸 등 다양한 형태로 제조될 수 있으나 이에 한정되는 것은 아니다.The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactants- Containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and may be formulated as a spray, but is not limited thereto. More specifically, flexible lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, hair tonic, hair cream, hair lotion, hair shampoo, hair It may be prepared in various forms such as solution, sol gel, emulsion, oil, wax, aerosol, such as rinse, hair conditioner, hair spray, hair aerosol, pomade, gel, etc., but is not limited thereto.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as carrier components. I can.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토오스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있으나 이에 한정되는 것은 아니다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydrocarbons, propane / It may include a propellant such as butane or dimethyl ether, but is not limited thereto.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나 이에 한정되는 것은 아니다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan may be used, but is not limited thereto.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나 이에 한정되는 것은 아니다.When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, ethoxylated isostearyl alcohol, suspending agents such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, crystallites Sex cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used, but the present invention is not limited thereto.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있으나 이에 한정되는 것은 아니다.When the formulation of the present invention is a surfactant containing cleansing, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester may be used, but is not limited thereto.
본 발명의 제형이 헤어샴푸인 경우에는 본 발명의 화합물에 증점제, 계면활성제, 점도 조절제, 보습제, pH 조절제, 방부제, 에션셜 오일 등과 같이 샴푸를 조성하기 위한 베이스 성분들을 혼합한다. 증점제로는 CDE가 사용될 수 있으며, 계면활성제로는 음이온 계면활성제인 LES과 양쪽성 계면활성제인 코코베타인, 점도조절제로는 폴리쿼터, 보습제로 글리세린, pH 조절제로 구연산, 수산화나트륨, 방부제로는 자몽 추출물이 사용될 수 있고, 이외에도 시더우드, 페퍼민트, 로즈마리 등의 에센셜 오일과, 실크아미노산, 펜타올, 비타민 E가 첨가될 수 있다. 본 발명의 한 구현예에 따르면, 상기 본 발명의 화합물을 100중량부로 할 때 CDE 5∼10 중량부, LES 30∼40 중량부, 코코베타인 10∼20 중량부, 폴리쿼터 0.1∼0.2 중량부, 글리세린 5∼10 중량부, 자몽 추출물 0.1∼1.01 중량부, 실크아미노산 0.5∼1 중량부, 펜타올 0.5∼1 중량부, 비타민 E 0.5∼2중량부, 에션셜 오일로 시더우드, 페퍼민트, 로즈마리 중에서 하나가 0.01∼0.1 중량부 혼합될 수 있으나 이에 한정되는 것은 아니다.When the formulation of the present invention is a hair shampoo, base components for forming a shampoo such as a thickener, a surfactant, a viscosity modifier, a moisturizer, a pH modifier, a preservative, and an essential oil are mixed with the compound of the present invention. CDE can be used as a thickener, and LES as an anionic surfactant and cocobetaine as an amphoteric surfactant as a surfactant, polyquarter as a viscosity modifier, glycerin as a moisturizer, citric acid as a pH modifier, sodium hydroxide, as a preservative Grapefruit extract may be used, and in addition, essential oils such as cedarwood, peppermint, and rosemary, silk amino acids, pen towels, and vitamin E may be added. According to one embodiment of the present invention, when the compound of the present invention is 100 parts by weight, 5 to 10 parts by weight of CDE, 30 to 40 parts by weight of LES, 10 to 20 parts by weight of cocobetain, 0.1 to 0.2 parts by weight of polyquarter , 5 to 10 parts by weight of glycerin, 0.1 to 1.01 parts by weight of grapefruit extract, 0.5 to 1 parts by weight of silk amino acid, 0.5 to 1 parts by weight of pentowel, 0.5 to 2 parts by weight of vitamin E, essential oil in cedarwood, peppermint, rosemary One may be mixed in an amount of 0.01 to 0.1 parts by weight, but is not limited thereto.
본 발명의 화장품 조성물에 포함되는 성분은 유효 성분으로서의 본 발명의 화합물과 담체 성분 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제를 포함할 수 있으나 이에 한정되는 것은 아니다.Ingredients included in the cosmetic composition of the present invention include ingredients commonly used in cosmetic compositions in addition to the compounds of the present invention and carrier ingredients as active ingredients, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances. It may include a conventional adjuvant, but is not limited thereto.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following examples and experimental examples are for illustrative purposes only, and the contents of the present invention are not limited by the following examples and experimental examples.
본 발명의 화합물의 합성 및 용해성 평가Synthesis and solubility evaluation of the compounds of the present invention
<1-1> <1-1> 펩타이드의 합성Peptide synthesis
<1-1-1> <1-1-1> 서열번호 3의 펩타이드의 합성Synthesis of the peptide of SEQ ID NO: 3
클로로트리틸클로라이드 수지(Chloro trityl chloride resin; CTL resin, Nova biochem [0064] Cat No. 01-64-0021) 700 ㎎을 반응 용기에 넣고 메틸렌클로라이드(MC) 10 ㎖를 가하여 3분간 교반하였다. 용액을 제거하고 디메틸포름아마이드(DMF) 10 ㎖를 넣어 3분간 교반한 후 다시 용매를 제거하였다. 반응기에 10 ㎖의 디클로로메탄 용액을 넣고 Fmoc-Cys(trt)-OH (Bachem, Swiss) 200 mmole 및 디이소프로필 에틸아민(DIEA) 400 mmole을 넣은 후 교반하여 잘 녹이고, 1시간 동안 교반하면서 반응시켰다. 반응 후 세척하고 메탄올과 DIEA(2:1)를 DCM(dichloromethane)에 녹여 10분간 반응시키고 과량의 DCM/DMF(1:1)로 세척하였다. 용액을 제거하고 디메틸포름아마이드(DMF)를 10 ㎖ 넣어 3분간 교반한 후 다시 용매를 제거하였다. 탈보호 용액(20%의 피페리딘/DMF) 10 ㎖를 반응 용기에 넣고 10분간 상온에서 교반한 후 용액을 제거하였다. 동량의 탈보호 용액을 넣고 다시 10분간 반응을 유지한 후 용액을 제거하고 각각 3분씩 DMF로 2회, MC로 1회, DMF로 1회 세척하여 Cys(trt)-CTL 수지를 제조하였다.Chloro trityl chloride resin (Chloro trityl chloride resin; CTL resin, Nova biochem Cat No. 01-64-0021) 700 mg was put into a reaction vessel, methylene chloride (MC) 10 ml was added and stirred for 3 minutes. The solution was removed, 10 ml of dimethylformamide (DMF) was added, stirred for 3 minutes, and the solvent was removed again. 10 ml of dichloromethane solution was added to the reactor, 200 mmole of Fmoc-Cys(trt)-OH (Bachem, Swiss) and 400 mmole of diisopropyl ethylamine (DIEA) were added, then stirred to dissolve well, and reacted with stirring for 1 hour. Made it. After the reaction was washed, methanol and DIEA (2:1) were dissolved in DCM (dichloromethane), reacted for 10 minutes, and washed with an excess of DCM/DMF (1:1). The solution was removed, 10 ml of dimethylformamide (DMF) was added, stirred for 3 minutes, and the solvent was removed again. 10 ml of a deprotection solution (20% piperidine/DMF) was placed in a reaction vessel and stirred at room temperature for 10 minutes, and then the solution was removed. The same amount of the deprotection solution was added and the reaction was maintained for another 10 minutes, and then the solution was removed and washed twice with DMF, once with MC, and once with DMF for 3 minutes each to prepare a Cys(trt)-CTL resin.
새로운 반응기에 10 ㎖의 DMF 용액을 넣고 Fmoc-His(trt)-OH(Bachem, Swiss) 200 mmole, HoBt 200 mmole 및 Bop 200 mmole을 넣은 후 교반하여 잘 녹였다. 반응기에 400mmole DIEA를 분획으로 2번에 걸쳐 넣은 후 모든 고체가 녹을 때까지 최소한 5분간 교반하였다. 녹인 아미노산 혼합 용액을 탈보호된 수지가 있는 반응 용기에 넣고 1시간 동안 상온에서 교반하면서 반응시켰다. 반응액을 제거하고 DMF 용액으로 3회 5분씩 교반한 후 제거하였다. 반응 수지를 소량 취하여 카이저 테스트(Nihydrin Test)를 이용하여 반응 정도를 점검하였다. 탈보호 용액으로 상기와 같이 동일하게 2번 탈보호 반응시켜 His(trt)-Cys(trt)-CTL 수지를 제조하였다. DMF와 MC로 충분히 세척하고 다시 한 번 카이저 테스트를 수행한 다음 상기와 동일하게 아래의 아미노산 부착 실험을 수행하였다.10 ml of DMF solution was added to a new reactor, 200 mmole of Fmoc-His(trt)-OH (Bachem, Swiss), 200 mmole of HoBt, and 200 mmole of Bop were added, followed by stirring to dissolve well. After adding 400mmole DIEA to the reactor twice as a fraction, the mixture was stirred for at least 5 minutes until all solids were dissolved. The dissolved amino acid mixture solution was placed in a reaction vessel with a deprotected resin and reacted with stirring at room temperature for 1 hour. The reaction solution was removed, and the mixture was stirred 3 times for 5 minutes with a DMF solution, and then removed. A small amount of the reaction resin was taken and the degree of reaction was checked using a Kaiser test (Nihydrin Test). A His(trt)-Cys(trt)-CTL resin was prepared by performing a deprotection reaction twice as described above with a deprotection solution. After sufficiently washing with DMF and MC, performing the Kaiser test again, the following amino acid adhesion experiment was performed in the same manner as above.
선정된 아미노산 서열에 의거하여 Fmoc-Cys(trt), Fmoc-Arg, Fmoc-Gln(trt), Fmoc-Val, Fmoc-Arg, Fmoc-Thr, Fmoc-Gln(trt) 및 Fmoc-Arg(pbf) 순으로 연쇄반응을 시켰다. Fmoc-보호기를 탈보호 용액으로 10분씩 2번 반응시킨 후 잘 세척하여 제거하였다. 무수 아세트산과 DIEA, HoBt를 넣어 1시간 동안 아세틸화를 수행한 뒤 제조된 펩티딜 수지를 DMF, MC 및 메탄올로 각각 3번을 세척하고, 질소 공기를 천천히 흘려 건조한 후, P2O5 하에서 진공으로 감압하여 완전히 건조한뒤 탈루 용액[트리플루오로아세트산 95%, 증류수 2.5%, 티오아니졸(Thioanisole) 2.5%] 30 ㎖을 넣은 후 상온에서 가끔 흔들어주며 2시간 반응을 유지하였다. 필터링을 하여 수지를 여과하였고, 수지를 소량의 TFA 용액으로 세척한 후 모액과 합하였다. 감압을 이용하여 전체 부피가 절반 정도 남도록 증류하고 50 ㎖의 차가운 에테르를 가하여 침전을 유도한 후, 원심분리하여 침전을 모으고, 2번 더 차가운 에테르로 세척하였다. 모액을 제거하고 질소 하에서 충분히 건조하여 정제 전 NH2-Arg-Gln-Thr-Arg-Val-Gln-Arg-Cys-His-Cys-OH 펩타이드(서열번호 3)를 0.65 g 합성하였다(수율: 92.6%). 분자량 측정기를 이용하여 측정시 분자량 1287.1(이론값 : 1286.5)를 얻을 수 있었다.Fmoc-Cys(trt), Fmoc-Arg, Fmoc-Gln(trt), Fmoc-Val, Fmoc-Arg, Fmoc-Thr, Fmoc-Gln(trt) and Fmoc-Arg(pbf) based on the selected amino acid sequence The chain reaction was carried out in order. The Fmoc-protecting group was reacted twice with a deprotection solution for 10 minutes each, and then washed well and removed. After performing acetylation for 1 hour by adding acetic anhydride, DIEA, and HoBt, the prepared peptidyl resin was washed three times with DMF, MC and methanol, and dried by slowly flowing nitrogen air, and then reduced pressure under P2O5 under vacuum After completely drying, 30 ml of a desulfurization solution [trifluoroacetic acid 95%, distilled water 2.5%, thioanisole 2.5%] was added, and the reaction was maintained for 2 hours by occasionally shaking at room temperature. The resin was filtered by filtering, and the resin was washed with a small amount of TFA solution and then combined with the mother liquor. After distillation using reduced pressure so that the total volume remains about half, 50 ml of cold ether was added to induce precipitation, and then the precipitate was collected by centrifugation and washed with cold ether twice. The mother liquor was removed and sufficiently dried under nitrogen to synthesize 0.65 g of NH 2 -Arg-Gln-Thr-Arg-Val-Gln-Arg-Cys-His-Cys-OH peptide (SEQ ID NO: 3) before purification (yield: 92.6 %). When measured using a molecular weight analyzer, a molecular weight of 1287.1 (theoretical value: 1286.5) could be obtained.
<1-1-2> <1-1-2> 서열번호 1 및 서열번호 2의 펩타이드의 합성Synthesis of the peptides of SEQ ID NO: 1 and SEQ ID NO: 2
상기 실시예 <1-1-1>과 동일한 방법을 이용하여 서열번호 1의 펩타이드(Glu-Leu-Ile-Glu-His-Gly-Gly-Gly-Arg-Pro-Ala-Asp: ELIEHGGGRPAD) 및 서열번호 2의 펩타이드(Ac-Tyr-Lys-Ser-Lys-Lys-Gly-Gly-Trp-Thr-His: Ac-YKSKKGGWTH)를 합성하였다.Peptide of SEQ ID NO: 1 (Glu-Leu-Ile-Glu-His-Gly-Gly-Gly-Arg-Pro-Ala-Asp: ELIEHGGGRPAD) and sequence using the same method as in Example <1-1-1> Peptide number 2 (Ac-Tyr-Lys-Ser-Lys-Lys-Gly-Gly-Trp-Thr-His: Ac-YKSKKGGWTH) was synthesized.
Sequence number
Amino acid sequence
<1-2> <1-2> 본 발명의 화합물의 합성Synthesis of the compounds of the present invention
펩타이트 반응기에 펩타이딜 레진 (1 mmol)과 N,N'-디이소프로필에틸아민 (DIPEA) 3.9 g (3 mmol, 3.0 equiv.)을 1-메틸-2-피롤리디논 (NMP) 10 mL에 녹인 후, 숙신산 무수물 200 mg (2 mmol, 2.0 equiv.)을 투입하여 상온에서 2시간 반응하였다. 용매를 필터하여 제거하고, 새로운 NMP (5 mL X 2)를 사용하여 세척하여 펩타이딜 레진-숙신산 결합체를 수득하였다. 1-히드록시벤조트리아졸 (HOBt) 270 mg (0.2 mmol, 2.0 equiv.)와 N,N,N',N'-테트라메틸-O-(1H-벤조트리아졸-1-일)우로니움 헥사플루오로포스페이트 (HBTU) 759 mg (0.2 mmol, 2.0 equiv.)를 디메틸설폭사이드 (DMSO) 10 mL에 녹이고 30분간 반응하였다. N,N-디이소프로필에틸아민 (DIPEA) 388 mg (0.3 mmol, 3 equiv.), 미녹시딜 유사체(analogue) (41.8)mg (0.2mM.), 및 펩타이딜 레진-숙신산 결합체 (0.1 mmol) 를 첨가하여 상온에서 72시간 동안 반응하고, 여과하여 반응된 펩타이딜 레진을 수득하였다. 수득된 레진을 절단 용액(cleavage solution)을 사용하여 상온에서 2시간 반응하여 레진 및 보호기를 제거하고 디에틸에테르 10 mL (10 mmol)을 사용하여 결정화하여 미녹시딜 하이브리드 펩타이드를 수득하였다.Peptidyl resin (1 mmol) and N,N'-diisopropylethylamine (DIPEA) 3.9 g (3 mmol, 3.0 equiv.) were added to the peptite reactor to 1-methyl-2-pyrrolidinone (NMP) 10 After dissolving in mL, 200 mg (2 mmol, 2.0 equiv.) of succinic anhydride was added and reacted at room temperature for 2 hours. The solvent was filtered off and washed with fresh NMP (5 mL X 2) to obtain a peptidyl resin-succinic acid conjugate. 1-hydroxybenzotriazole (HOBt) 270 mg (0.2 mmol, 2.0 equiv.) and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 759 mg (0.2 mmol, 2.0 equiv.) of hexafluorophosphate (HBTU) was dissolved in 10 mL of dimethyl sulfoxide (DMSO) and reacted for 30 minutes. N,N-diisopropylethylamine (DIPEA) 388 mg (0.3 mmol, 3 equiv.), minoxidyl analog (41.8) mg (0.2 mM.), and peptidyl resin-succinic acid conjugate (0.1 mmol) Was added, reacted at room temperature for 72 hours, and filtered to obtain a reacted peptidyl resin. The obtained resin was reacted for 2 hours at room temperature using a cleavage solution to remove the resin and the protecting group, and crystallized using 10 mL (10 mmol) of diethyl ether to obtain a minoxidil hybrid peptide.
[반응식 1] 미녹시딜과 펩타이드의 결합체의 반응식 [Scheme 1] Reaction scheme of conjugate of minoxidil and peptide
[반응식 2] 미녹시딜-노킨 결합체의 반응식[Reaction Scheme 2] Reaction Scheme of Minoxidyl-Nokine Conjugate
[반응식 3] 미녹시딜-케라민2 결합체의 반응식[Scheme 3] Reaction scheme of minoxidyl-
[반응식 4] 미녹시딜-WINT 결합체의 반응식[Reaction Scheme 4] Reaction Scheme of Minoxidyl-WINT Conjugate
<1-3> <1-3> 용해성 평가Solubility evaluation
상기 실시예 <1-1>에서 제조된 미녹시딜-CG-노킨, 미녹시딜-CG-케라민2, 미녹시딜-CG-WINT를 각각 10mg/ml의 농도로 DW에 용해시켰다. 대조군으로는 미녹시딜을 사용하였다.Minoxidil-CG-Nokine, minoxidil-CG-
그 결과, 미녹시딜의 경우 동일 농도에서 물에 거의 용해되지 않아 불투명한 상태를 나타낸 반면에, 본 발명의 화합물 3종은 모두 물에 완전히 용해됨을 확인하였다(도 1 참조).As a result, it was confirmed that minoxidil was hardly soluble in water at the same concentration and thus showed an opaque state, whereas all three compounds of the present invention were completely soluble in water (see FIG. 1).
본 발명의 화합물 처리시 세포 증식 정도 평가Evaluation of the degree of cell proliferation upon treatment with the compound of the present invention
<2-1> <2-1> 인간 human 제대정맥Umbilical vein 혈관내피세포(Human umbilical vein endothelial cell, HUVEC)에 대한 세포 증식 정도 평가 Evaluation of cell proliferation for human umbilical vein endothelial cells (HUVEC)
실시예 1에서 합성된 본 발명의 화합물의 기능을 확인하기 위하여 HUVEC에 본 발명의 화합물을 처리하여 증식 정도를 확인하였다. HUVEC을 96웰 플레이트에 3000개씩 넣고 24시간 동안 CO2 배양기에서 배양하였다. 24시간 후에 무혈청 DMEM 배지로 변경하고, 실시예 1에서 합성된 본 발명의 화합물 3종과 미녹시딜을 각각 0.5uM, 5uM, 50uM 농도로 세포에 처리한 후 72시간 동안 배양하였다. 배양이 완료된 후 배양 상층액을 제거하고 에탄올을 이용하여 세포를 고정한 후, PBS(phosphate buffer saline)로 3회 세척하였다. 세척 용액을 제거한 뒤 비색 SRB 용액으로 처리하고 1% 아세트산으로 충분히 세척을 한 뒤 현미경으로 세포를 관찰하여 생존 세포의 상태를 관찰하였으며, 염색된 세포들에 10mM 트리스마 베이스(pH 10.5) 용액을 가하여 SRB를 용출시킨 후 자외선 560nm 파장에서 흡광도를 측정하여 세포의 생존 상태를 측정하였다.In order to confirm the function of the compound of the present invention synthesized in Example 1, the degree of proliferation was confirmed by treating the compound of the present invention with HUVEC. Each of 3000 HUVECs was placed in a 96-well plate and incubated in a CO 2 incubator for 24 hours. After 24 hours, it was changed to serum-free DMEM medium, and the three compounds of the present invention synthesized in Example 1 and minoxidil were treated on the cells at concentrations of 0.5uM, 5uM, and 50uM, respectively, and cultured for 72 hours. After the culture was completed, the culture supernatant was removed, the cells were fixed using ethanol, and then washed three times with PBS (phosphate buffer saline). After removing the washing solution, treatment with a colorimetric SRB solution, and after sufficiently washing with 1% acetic acid, the cells were observed under a microscope to observe the state of viable cells, and a 10 mM Trisma base (pH 10.5) solution was added to the stained cells. After the SRB was eluted, the absorbance was measured at a wavelength of 560 nm of ultraviolet light to measure the viability of the cells.
그 결과, 본 발명의 화합물 3종의 경우 낮은 농도에서는 대조군인 미녹시딜과 유사한 세포 증식을 나타냈으나, 농도가 증가할수록 미녹시딜에 비해서 세포 증식 정도가 현저히 증가하는 것을 알 수 있었다(도 2 참조).As a result, in the case of the three compounds of the present invention, at a low concentration, cell proliferation was similar to that of minoxidil, which is a control, but as the concentration increased, the degree of cell proliferation was significantly increased compared to minoxidil (see FIG. 2).
<2-2> <2-2> 인간 모발 진피 유두 세포(Human Hair Dermal Papilla Cells, Human Hair Dermal Papilla Cells ( HHDPCHHDPC )에 대한 세포 증식 평가) Cell proliferation evaluation
HHDPC를 96웰 플레이트에 각 웰당 3000세포씩 넣고, 24시간 동안 CO2 배양기에서 배양하였다. 무혈청 DMEM 배지로 변경한 후에 본 발명의 화합물 3종과 미녹시딜을 각각 0.5uM, 5uM, 50uM 농도로 처리하였고, 72시간 동안 배양하였다. 배양 완료 후에 상기 실시예 <2-1>의 방법과 동일한 방법으로 세포를 염색하여 SRB를 용출하여 세포 증식 정도를 수치화하였다.HHDPC was put into a 96-well plate at a rate of 3000 cells per well, and cultured in a CO 2 incubator for 24 hours. After changing to a serum-free DMEM medium, the three compounds of the present invention and minoxidil were treated at concentrations of 0.5uM, 5uM, and 50uM, respectively, and cultured for 72 hours. After completion of the culture, cells were stained in the same manner as in Example <2-1>, and SRB was eluted to quantify the degree of cell proliferation.
그 결과, 본 발명의 화합물 3종은 미녹시딜에 비해서 세포 증식 정도가 높았고, 처리 농도에 비례하여 세포 증식 정도도 현저히 높아지는 것이 확인되었다(도 3 참조).As a result, it was confirmed that the degree of cell proliferation was higher in the three compounds of the present invention compared to minoxidil, and the degree of cell proliferation was significantly increased in proportion to the treatment concentration (see Fig. 3).
본 발명의 화합물의 VEGF, TGFβ1 발현에 대한 영향 평가Evaluation of the effect of the compounds of the present invention on the expression of VEGF and TGFβ1
VEGF는 혈관 생성 및 확장 기능에 역할을 하고, TGFβ1은 탈모에 영향을 주기 때문에, 본 발명의 화합물 처리시 VEGF와 TGFβ1의 발현 정도를 확인하였다.Since VEGF plays a role in angiogenesis and dilation functions, and TGFβ1 affects hair loss, the expression levels of VEGF and TGFβ1 were confirmed when the compounds of the present invention were treated.
<3-1> <3-1> mRNA 량 평가(전사 수준)Evaluation of the amount of mRNA (transcription level)
VEGF의 발현은 HUVEC을 이용하였고, TGFβ1 발현은 모낭 모유두 진피 세포(Hair follicle dermal papilla cell)를 이용하였다. 두 세포를 각각 6웰 플레이트에 각 웰당 1×105 세포씩 넣었다. 24시간 동안 CO2 배양기에서 배양한 후, 무혈청 DMEM 배지로 변경하였고, 본 발명의 화합물 3종과 미녹시딜을 5uM, 50uM 농도로 세포에 처리한 후 24시간 동안 배양하였다. 배양이 완료된 세포를 회수하고, RNA 추출 키트를 이용하여 RNA를 추출한 후 RT-PCR하여 VEGF와 TGFβ1 발현 정도를 확인하였다. RT-PCR시에 사용한 프라이머는 표 2에 나타내었다.HUVEC was used for VEGF expression, and hair follicle dermal papilla cells were used for TGFβ1 expression. Each of the two cells was placed in a 6-well plate with 1×10 5 cells per well. After culturing in a CO 2 incubator for 24 hours, it was changed to a serum-free DMEM medium, and the cells were treated with 3 kinds of compounds of the present invention and minoxidil at concentrations of 5 uM and 50 uM, and then cultured for 24 hours. The cultured cells were recovered, RNA was extracted using an RNA extraction kit, and RT-PCR was performed to check the level of expression of VEGF and TGFβ1. The primers used during RT-PCR are shown in Table 2.
그 결과, 본 발명의 화합물 3종은 미녹시딜에 비해서 VEGF 발현량이 높게 나타났고, 특히 미녹시딜-노킨과 미녹시딜-케라민2의 경우 미녹시딜보다 VEGF 발현량이 현저히 높았다(도 4 내지 도 6 참조). 또한, TGFβ1 발현 양상은 본 발명의 화합물 3종이 미녹시딜에 비해서 낮았고, 특히 미녹시딜-노킨이 동일 농도에서 미녹시딜보다 TGFβ1 발현량이 현저히 낮았다(도 4 내지 도 6 참조). 이와 같은 결과로부터, 본 발명의 화합물 3종이 미녹시딜에 비해서 혈관 생성 및 확장 기능에 역할을 하는 VEGF 발현량이 높고, 탈모에 관여하는 TGFβ1 발현량이 낮기 때문에 본 발명의 화합물 3종을 탈모 방지 또는 개선에 이용할 수 있음을 알 수 있다.As a result, the three compounds of the present invention showed a higher VEGF expression than minoxidil, and in particular, minoxidil-nokin and minoxidil-
<3-2> <3-2> 단백질량 평가(번역물 수준)Protein content evaluation (translation level)
HUVEC을 6웰 플레이트에 각 웰당 1×105 세포씩 넣었다. 24시간 동안 CO2 배양기에서 배양하였다. 무혈청 DMEM 배지로 변경한 후 본 발명의 화합물 3종과 미녹시딜을 5uM, 50uM 농도로 세포에 처리한 후 24시간 동안 배양하였다. 단백질 추출 키트를 이용하여 단백질을 추출한 후 웨스턴 블랏을 실시하였다. 12% SDS-PAGE를 제조한 후, 제조된 SDS-PAGE 에 15ug의 단백질을 로딩하였으며, PVDF 멤브레인에 트랜스퍼하였다. 상온에서 1시간 동안 5% 탈지 분유 용액으로 블락킹하였다. 1/3000의 농도로 2시간 동안 상온에서 1차 항체(anti-VEGF antibody, anti-alpha tubulin antibody)를 붙였다. PBST로 10분 동안 3회 세척하였고, 1/5000의 농도로 1시간 동안 상온에서 2차 항체를 붙였다. BST로 15분 동안 3회 세척한 후에 검출하였다.HUVECs were placed in a 6-well plate at 1×10 5 cells per well. Incubated in a CO 2 incubator for 24 hours. After changing to a serum-free DMEM medium, the cells were treated with 3 kinds of compounds of the present invention and minoxidil at concentrations of 5uM and 50uM, and cultured for 24 hours. After protein extraction using a protein extraction kit, Western blot was performed. After preparing 12% SDS-PAGE, 15 ug of protein was loaded on the prepared SDS-PAGE, and transferred to a PVDF membrane. Blocking was performed with a 5% skim milk powder solution for 1 hour at room temperature. A primary antibody (anti-VEGF antibody, anti-alpha tubulin antibody) was applied at room temperature for 2 hours at a concentration of 1/3000. Washed three times for 10 minutes with PBST, and a secondary antibody was attached at room temperature for 1 hour at a concentration of 1/5000. It was detected after washing 3 times for 15 minutes with BST.
그 결과, 본 발명의 화합물 3종이 미녹시딜과 유사하거나, 미녹시딜에 비해서 VEGF 발현량이 높은 것을 알 수 있었다(도 7 참조). 본 발명의 화합물 3종이 혈관 생성 및 확장 기능에 역할하는 VEGF 발현을 증가시키므로, 본 발명의 화합물을 탈모 방지 또는 개선에 유용하게 쓸 수 있다.As a result, it was found that the three compounds of the present invention were similar to minoxidil, or the VEGF expression level was higher than that of minoxidil (see FIG. 7). Since the three compounds of the present invention increase the expression of VEGF, which plays a role in angiogenesis and dilation, the compounds of the present invention can be usefully used for preventing or improving hair loss.
본 발명의 화합물의 혈관 형성 정도 평가Evaluation of the degree of blood vessel formation of the compounds of the present invention
24웰 플레이트에 마트리젤을 200㎕씩 첨가하고 1시간 배양하였다. 마트리젤에 HUVEC을 1×105 세포씩 넣었다. 세포가 씨딩된 마트리젤에 본 발명의 화합물 3종과 미녹시딜을 각각 5uM, 50uM의 농도로 처리하였다. 양성 대조군으로 사용한 VEGF 는 50nM, 100nM 의 농도로 처리하였다. 6시간 후 현미경을 통해 HUVEC의 혈관 형성 정도를 관찰하였다.200 µl of Matrigel was added to a 24-well plate and incubated for 1 hour. HUVECs were added to Matrigel by 1×10 5 cells each. Three kinds of compounds of the present invention and minoxidil were treated on the cell-seeded matrigel at concentrations of 5uM and 50uM, respectively. VEGF used as a positive control was treated at concentrations of 50nM and 100nM. After 6 hours, the degree of blood vessel formation of HUVECs was observed through a microscope.
그 결과, 본 발명의 화합물 3종을 처리한 경우 혈관 형성 정도가 우수하였으며, 특히 미녹시딜보다 우수하며, VEGF 처리시와 유사한 정도로 혈관을 형성하였다(도 8 참조). 각 실험군의 혈관 형성 정도를 일정 단위 면적 내에서 완전하게 형성된 혈관 개수로 비교하였을 때, 본 발명의 화합물 3종은 미녹시딜에 비해서 상대적으로 우수한 혈관 형성을 보이는 것으로 나타났다(도 9 참조).As a result, when the three compounds of the present invention were treated, the degree of blood vessel formation was excellent, particularly better than minoxidil, and blood vessels were formed to a similar degree to that of the VEGF treatment (see FIG. 8). When the degree of blood vessel formation in each experimental group was compared with the number of blood vessels completely formed within a certain unit area, it was found that the three compounds of the present invention showed relatively superior blood vessel formation compared to minoxidil (see FIG. 9).
본 발명의 Of the present invention 미녹시딜Minoxidil -- WINT가WINT WINT의WINT 신호 경로인 베타- Signaling pathway beta- 카테닌의Catenic 핵 nucleus 전좌에In front 관여하는지 확인 Make sure you are involved
모낭 진피 유두 세포(Hair follicle dermal papilla cell)을 6웰 플레이트에 각 웰당 1×105 세포씩 넣었다. 24시간 동안 CO2 배양기에서 배양하였다. 무혈청 DMEM 배지로 변경 후 미녹시딜, 미녹시딜-WINT, WINT를 5uM, 50uM 농도로 세포에 처리한 후 24시간 동안 배양하였다. 단백질 추출 키트를 이용하여 단백질을 추출(핵/세포질 단백질 각각 추출)하였다. 1차 항체로 항-베타 카테닌 항체, 항-HDAC 항체, 항-알파 튜불린 항체를 사용한 것 외에는 실시예 <3-2>의 방법과 동일하게 웨스턴 블랏을 실시하였다.Hair follicle dermal papilla cells (Hair follicle dermal papilla cells) were placed in a 6-well plate for each well 1 × 10 5 cells. Incubated in a CO 2 incubator for 24 hours. After changing to a serum-free DMEM medium, cells were treated with minoxidil, minoxidil-WINT, and WINT at concentrations of 5uM and 50uM, and cultured for 24 hours. Proteins were extracted (nuclear/cytoplasmic proteins, respectively) using a protein extraction kit. Western blot was performed in the same manner as in Example <3-2>, except that anti-beta catenin antibody, anti-HDAC antibody, and anti-alpha tubulin antibody were used as the primary antibody.
그 결과, 동일한 농도에서 본 발명의 화합물인 미녹시딜-WINT는 베타-카테닌의 핵으로의 전좌가 확인된 반면에, 미녹시딜 단독은 베타-카테닌의 핵으로의 전좌를 일으키는 정도가 현저히 낮은 것으로 확인되었다(도 10 참조). 미녹시딜-WINT의 핵으로의 전좌는 미녹시딜 단독에 비해서 최대 2.8배 이상인 것으로 확인되었다(도 11 참조). 이와 같은 결과로부터 본 발명의 화합물인 미녹시딜-WINT도 WINT의 신호 경로인 베타-카테닌을 핵 내로 전달하는 것이 가능하고, 미녹시딜보다도 베타-카테닌의 핵 전좌를 일으키는 정도가 높으므로 본 발명의 화합물을 발모 촉진 또는 탈모 방지에 이용할 수 있다.As a result, at the same concentration, it was confirmed that the translocation of beta-catenin to the nucleus was confirmed in minoxidil-WINT, which is the compound of the present invention, whereas the translocation of minoxidil alone to the nucleus of beta-catenin was remarkably low ( See Figure 10). The translocation of minoxidil-WINT to the nucleus was confirmed to be at least 2.8 times higher than that of minoxidil alone (see FIG. 11). From these results, minoxidil-WINT, a compound of the present invention, can also deliver beta-catenin, a signaling pathway of WINT, into the nucleus, and the degree of causing nuclear translocation of beta-catenin is higher than that of minoxidil. It can be used to promote or prevent hair loss.
본 발명의 Of the present invention 미녹시딜Minoxidil -- 노킨이Nokini Nokkin의Nokkin's 신호 경로인 Signal path phosphophospho -- Smad1Smad1 /5/8의 핵 전좌에 관여하는지 확인Make sure you are involved in the nuclear translocation of /5/8
본 발명의 미녹시딜-노킨이 모발 손실의 주요 인자인 BMP 신호 경로를 저해하는지 여부를 phospho-Smad1/5/8 활성화(세포질에서 핵 내로의 이동) 저해로 확인하였다. 실시예 5의 방법과 동일하게 하였고, BMP2 존재 하에서 미녹시딜-WINT대신에 미녹시딜-노킨을 처리하고, 1차 항체는 항-P-Smad1/5/8 항체, 항-HDAC1 항체를 사용한 것만 다르게 하여 실험을 진행하였다.Whether the minoxidil-nokin of the present invention inhibits the BMP signaling pathway, which is a major factor in hair loss, was confirmed by inhibition of phospho-Smad1/5/8 activation (migration from the cytoplasm to the nucleus). In the same manner as in Example 5, in the presence of BMP2, minoxidil-Nokine was treated instead of minoxidil-WINT, and the primary antibody was anti-P-Smad1/5/8 antibody, and only anti-HDAC1 antibody was used. Proceeded.
그 결과, 미녹시딜-노킨 처리시에는 미녹시딜 처리시와 비교해서 P-Smad1/5/8를 핵 내로 전달이 감소되는 것으로 나타났고, 미녹시딜-노킨의 농도가 높아질수록 핵 내의 P-Smad1/5/8는 더 감소하는 것으로 나타났다(도 12 및 도 13 참조). 이 결과로부터 본 발명의 미녹시딜-노킨이 모발 손실에 대한 BMP 신호 경로를 차단할 수 있으므로, 본 발명의 미녹시딜-노킨을 발모 촉진 또는 탈모 방지에 이용할 수 있다.As a result, it was found that the delivery of P-Smad1/5/8 into the nucleus was decreased during the treatment with minoxidil-nokin compared to the treatment with minoxidil, and the higher the concentration of minoxidil-nokin, the more P-Smad1/5/8 in the nucleus. Was found to decrease further (see FIGS. 12 and 13). From this result, since the minoxidil-nokin of the present invention can block the BMP signaling pathway for hair loss, the minoxidil-nokin of the present invention can be used to promote hair growth or prevent hair loss.
본 발명의 화합물 처리시 모발 생장 확인Confirmation of hair growth during treatment with the compound of the present invention
7주령 C57BL 수컷 마우스 6마리에 본 발명의 미녹시딜-노킨을 발라서 모발 생장 정도를 확인하였다. C57BL/6 7주령 마우스의 등털을 제모 크림을 이용하여 모두 제모하였다. PBS에 미녹시딜 및 미녹시딜-노킨을 각각 100ug/ml의 농도로 첨가하여 시료를 제조하였다. 매일 하루에 한번씩 마우스의 등 피부에 골고루 발라주었다. 마우스의 등 피부털이 자라나는지 관찰한 후 등 피부색이 검게 변하는 시점으로부터 사진 촬영하여 관찰하였다. 조직학 검사를 위해서 마우스를 도살하고, 마우스의 등피부를 채취하여 4% PFA에 고정한 후 파라핀으로 포매하였다. 포매된 블록을 4um로 섹션하여 H&E 염색한 후 모낭을 관찰하였다.The degree of hair growth was confirmed by applying the minoxidil-nokin of the present invention to six 7-week-old C57BL male mice. All of the back hairs of C57BL/6 7-week-old mice were removed using a hair removal cream. Samples were prepared by adding minoxidil and minoxidil-nokin in PBS at a concentration of 100 ug/ml, respectively. It was evenly applied to the back skin of the mouse once a day every day. After observing whether the back skin hair of the mouse grows, a picture was taken and observed from the point when the back skin color turned black. For histological examination, the mice were slaughtered, the back skin of the mouse was collected, fixed in 4% PFA, and embedded with paraffin. The embedded block was sectioned into 4 μm, stained with H&E, and hair follicles were observed.
그 결과, 본 발명의 화합물을 바른 경우에는 시료를 처리하지 않은 대조군이나, 미녹시딜을 처리한 군에 비해서 모발 생장 속도가 현저히 빠른 것을 확인하였다(도 14 참조). H&E 검사로 모낭을 확인하였을 때, 본 발명의 화합물을 처리한 군은 대조군이나, 미녹시딜을 처리한 군에 비해서 모낭이 피부 깊숙이 위치하고 있었고, 모낭의 개수가 더 많았으며, 모낭 내의 모근이 길게 성장하여 피부의 표면으로 자라는 형태로 모낭의 성장과 발달이 촉진된 것을 확인하였다(도 15 참조). 위와 같은 결과로부터 본 발명의 화합물을 발모 촉진 또는 탈모 방지에 이용할 수 있음을 알 수 있다.As a result, when the compound of the present invention was applied, it was confirmed that the hair growth rate was significantly faster than that of the control group not treated with the sample or the group treated with minoxidil (see FIG. 14). When the hair follicles were identified by the H&E test, the group treated with the compound of the present invention had the hair follicles located deeper in the skin and the number of hair follicles was greater than the control group or the group treated with minoxidil. It was confirmed that the growth and development of hair follicles was promoted in the form of growing to the surface of the skin (see FIG. 15). From the above results, it can be seen that the compound of the present invention can be used to promote hair growth or prevent hair loss.
[제형예][Formulation example]
제형예 1: 유연화장수Formulation Example 1: Softening lotion
상기 실시예 <1-2>에서 제조된 본 발명의 화합물을 포함하며, 하기 조성으로 이루어진 유연화장수를 일반적인 화장수 제조방법에 따라 제조하였다.A flexible lotion comprising the compound of the present invention prepared in Example <1-2> and consisting of the following composition was prepared according to a general lotion preparation method.
제형예Formulation example 2. 영양크림 2. Nourishing cream
상기 실시예 <1-2>에서 제조된 본 발명의 화합물을 포함하며, 하기 조성으로 이루어진 영양크림을 일반적인 영양크림 제조방법에 따라 제조하였다.A nourishing cream comprising the compound of the present invention prepared in Example <1-2> and having the following composition was prepared according to a general nourishing cream preparation method.
제형예Formulation example 3. 영양화장수 3. Nutritional lotion
상기 실시예 <1-2>에서 제조된 본 발명의 화합물을 포함하며, 하기 조성으로 이루어진 영양화장수를 일반적인 화장수 제조방법에 따라 제조하였다.A nutrient lotion containing the compound of the present invention prepared in Example <1-2> and consisting of the following composition was prepared according to a general lotion preparation method.
제형예Formulation example 4. 에센스 4. Essence
상기 실시예 <1-2>에서 제조된 본 발명의 화합물을 포함하며, 하기 조성으로 이루어진 에센스를 일반적인 에센스 제조방법에 따라 제조하였다.An essence comprising the compound of the present invention prepared in Example <1-2> and consisting of the following composition was prepared according to a general essence preparation method.
제형예Formulation example 5. 5. 헤어세럼Hair serum
상기 실시예 <1-2>에서 제조된 본 발명의 화합물을 포함하며, 하기 조성으로 이루어진 헤어세럼를 일반적인 헤어세럼 제조방법에 따라 제조하였다.A hair serum comprising the compound of the present invention prepared in Example <1-2> and having the following composition was prepared according to a general hair serum manufacturing method.
제형예Formulation example 6. 6. 헤어토너Hair toner
상기 실시예 <1-2>에서 제조된 본 발명의 화합물을 포함하며, 하기 조성으로 이루어진 헤어세럼을 일반적인 헤어세럼 제조방법에 따라 제조하였다.A hair serum comprising the compound of the present invention prepared in Example <1-2> and having the following composition was prepared according to a general hair serum manufacturing method.
상기에서는 본 발명의 바람직한 실시예를 예시적으로 설명하였으나, 본 발명의 범위는 상기와 같은 특정 실시예에만 한정되지 아니하며, 해당 분야에서 통상의 지식을 가진 자라면 본 발명의 특허청구범위에 기재된 범주 내에서 적절하게 변경이 가능할 것이다.In the above, preferred embodiments of the present invention have been exemplarily described, but the scope of the present invention is not limited to the specific embodiments as described above, and those of ordinary skill in the relevant field have the scope described in the claims of the present invention. It will be possible to change appropriately within.
<110> CAREGEN CO., LTD. <120> CONJUGATE OF MINOXIDIL AND PEPTIDE <130> 2016-DPA-1464 <160> 9 <170> KopatentIn 2.0 <210> 1 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> WINT peptide <400> 1 Glu Leu Ile Glu His Gly Gly Gly Arg Pro Ala Asp 1 5 10 <210> 2 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Keramin2 peptide <400> 2 Tyr Lys Ser Lys Lys Gly Gly Trp Thr His 1 5 10 <210> 3 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Nokkin peptide <400> 3 Arg Gln Thr Arg Val Gln Arg Cys His Cys 1 5 10 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> VEGF Forward <400> 4 ccatgaactt tctgctgtct t 21 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> VEGF Reverse <400> 5 tcgatcgttc tgtatcagtc t 21 <210> 6 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> TGFb1 Forward <400> 6 gccctggata ccaactattg c 21 <210> 7 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> TGFb1 Reverse <400> 7 tcagcacttg caggagtagc g 21 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Forward <400> 8 ggagccaaaa gggtcatcat 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Reverse <400> 9 gtgatggcat ggactgtggt 20 <110> CAREGEN CO., LTD. <120> CONJUGATE OF MINOXIDIL AND PEPTIDE <130> 2016-DPA-1464 <160> 9 <170> KopatentIn 2.0 <210> 1 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> WINT peptide <400> 1 Glu Leu Ile Glu His Gly Gly Gly Arg Pro Ala Asp 1 5 10 <210> 2 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Keramin2 peptide <400> 2 Tyr Lys Ser Lys Lys Gly Gly Trp Thr His 1 5 10 <210> 3 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Nokkin peptide <400> 3 Arg Gln Thr Arg Val Gln Arg Cys His Cys 1 5 10 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> VEGF Forward <400> 4 ccatgaactt tctgctgtct t 21 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> VEGF Reverse <400> 5 tcgatcgttc tgtatcagtc t 21 <210> 6 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> TGFb1 Forward <400> 6 gccctggata ccaactattg c 21 <210> 7 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> TGFb1 Reverse <400> 7 tcagcacttg caggagtagc g 21 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Forward <400> 8 ggagccaaaa gggtcatcat 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Reverse <400> 9 gtgatggcat ggactgtggt 20
Claims (7)
상기 펩타이드는 펩타이드 결합에 의해 아미노산 잔기들이 서로 결합되어 형성된 선형의 분자이고,
상기 펩타이드는 8 내지 30개의 아미노산 서열로 이루어지는 수용성 펩타이드이며,
상기 수용성 펩타이드는 친수성 측쇄를 갖는 아미노산의 비율이 50% 내지 100%이고, 소수성 측쇄를 갖는 아미노산의 비율이 0% 내지 50%인 펩타이드이며,
상기 친수성 측쇄를 갖는 아미노산은 아르기닌(Arg), 히스티딘(His), 리신(Lys), 아스파라긴산(Asp), 글루탐산(Glu), 세린(Ser), 트레오닌(Thr), 아스파라긴(Asn), 글루타민(Gln), 시스테인(Cys), 셀레노시스테인(Sec), 글리신(Gly) 및 프롤린(Pro)으로 이루어진 군으로부터 선택되고,
상기 소수성 측쇄를 갖는 아미노산은 알라닌(Ala), 발린(Val), 이소루이신(Ile), 루이신(Leu), 메티오닌(Met), 페닐알라닌(Phe), 티로신(Tyr) 및 트립토판(Trp)으로 이루어진 군으로부터 선택되는 화합물.As a compound having a structure in which minoxidil and peptide are covalently linked,
The peptide is a linear molecule formed by bonding of amino acid residues to each other by a peptide bond,
The peptide is a water-soluble peptide consisting of 8 to 30 amino acid sequences,
The water-soluble peptide is a peptide in which the proportion of amino acids having a hydrophilic side chain is 50% to 100%, and the proportion of amino acids having a hydrophobic side chain is 0% to 50%,
The amino acids having the hydrophilic side chain are arginine (Arg), histidine (His), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu), serine (Ser), threonine (Thr), asparagine (Asn), glutamine (Gln). ), cysteine (Cys), selenocysteine (Sec), glycine (Gly), and selected from the group consisting of proline (Pro),
The amino acids having the hydrophobic side chain are alanine (Ala), valine (Val), isoleucine (Ile), leucine (Leu), methionine (Met), phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp). A compound selected from the group consisting of.
상기 펩타이드는 8 내지 15개의 아미노산 서열로 이루어지는 화합물.The method according to claim 1,
The peptide is a compound consisting of 8 to 15 amino acid sequences.
상기 수용성 펩타이드는 친수성 측쇄를 갖는 아미노산의 비율이 70% 내지 100%인 화합물.The method according to claim 1,
The water-soluble peptide is a compound in which the proportion of amino acids having a hydrophilic side chain is 70% to 100%.
상기 수용성 펩타이드는 친수성 측쇄를 갖는 아미노산의 비율이 90% 내지 100%인 화합물.The method of claim 3,
The water-soluble peptide is a compound in which the proportion of amino acids having a hydrophilic side chain is 90% to 100%.
상기 수용성 펩타이드는 소수성 측쇄를 갖는 아미노산이 0개 내지 5개인 화합물.The method according to claim 1,
The water-soluble peptide is a compound having 0 to 5 amino acids having a hydrophobic side chain.
상기 수용성 펩타이드는 소수성 측쇄를 갖는 아미노산이 0개 내지 3개인 화합물.The method of claim 5,
The water-soluble peptide is a compound having 0 to 3 amino acids having a hydrophobic side chain.
상기 펩타이드는 서열번호 1의 아미노산 서열로 구성되는 노킨 펩타이드, 서열번호 2의 아미노산 서열로 구성되는 케라민2 펩타이드 및 서열번호 3의 아미노산 서열로 구성되는 WINT 펩타이드로 이루어진 군으로부터 선택되는 화합물.The method according to claim 1,
The peptide is a compound selected from the group consisting of a Nokin peptide consisting of the amino acid sequence of SEQ ID NO: 1, a keramine 2 peptide consisting of the amino acid sequence of SEQ ID NO: 2, and a WINT peptide consisting of the amino acid sequence of SEQ ID NO: 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190005700A KR102160566B1 (en) | 2019-01-16 | 2019-01-16 | Conjugate of minoxidil and peptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190005700A KR102160566B1 (en) | 2019-01-16 | 2019-01-16 | Conjugate of minoxidil and peptide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160105707A Division KR101948238B1 (en) | 2016-08-19 | 2016-08-19 | Conjugate of minoxidil and peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190009402A KR20190009402A (en) | 2019-01-28 |
KR102160566B1 true KR102160566B1 (en) | 2020-09-28 |
Family
ID=65269854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190005700A KR102160566B1 (en) | 2019-01-16 | 2019-01-16 | Conjugate of minoxidil and peptide |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102160566B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101948238B1 (en) | 2016-08-19 | 2019-02-14 | (주)케어젠 | Conjugate of minoxidil and peptide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507719B2 (en) | 2003-07-18 | 2009-03-24 | Institut European De Biologie Cellulaire | Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101021197B1 (en) | 2008-04-11 | 2011-03-11 | (주)케어젠 | Growth Factor?Mimicking Peptides and Uses Thereof |
KR101163171B1 (en) | 2009-01-20 | 2012-07-19 | (주)케어젠 | Noggin derived Peptides and Uses Thereof |
KR101198918B1 (en) | 2009-09-01 | 2012-11-07 | (주)케어젠 | WNT10 Derived Peptides and Uses Thereof |
KR20120011632A (en) | 2010-07-29 | 2012-02-08 | 애경산업(주) | Hair cleansing composition containing minoxidil and process for preparing the same |
KR101285259B1 (en) * | 2011-08-04 | 2013-07-11 | (주)케어젠 | WNT family Derived Peptides and Uses Thereof |
-
2019
- 2019-01-16 KR KR1020190005700A patent/KR102160566B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507719B2 (en) | 2003-07-18 | 2009-03-24 | Institut European De Biologie Cellulaire | Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment |
Also Published As
Publication number | Publication date |
---|---|
KR20190009402A (en) | 2019-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2435723T3 (en) | Peptides that have epidermal growth factor activities and their uses | |
JP2021080273A (en) | Conjugate of minoxidil and peptide | |
JP2021011507A (en) | Conjugate of finasteride with peptide | |
KR102160566B1 (en) | Conjugate of minoxidil and peptide | |
AU2017399481B2 (en) | Conjugate of salicylic acid and peptide | |
US20230181441A1 (en) | Trolox-peptide conjugate and use thereof | |
KR102016658B1 (en) | Conjugate of salicylic acid and peptide | |
KR102093209B1 (en) | Conjugate of isotretinoin and peptide | |
KR20180125419A (en) | Conjugate of isotretinoin and peptide | |
OA19189A (en) | Conjugate of Minoxidil and Peptide. | |
EA041180B1 (en) | SALICYLIC ACID AND PEPTIDE CONJUGATE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |